Clinical operations
How to Test an Oncology CRA’s Safety Escalation Judgment
Use a fictional pre-dose lab case and a three-part scoring rubric to assess how oncology CRAs verify, escalate, and follow up on potential safety issues.
By Lampgen Clinical Research

3 min read · estimated
What the source reported
A structured oncology CRA interview can show how a candidate responds to a possible safety issue before taking on a site. Use a fictional case involving a protocol-required safety lab, then listen for what the candidate would verify, whom they would alert, and how they would confirm that the issue was addressed.
FDA’s final ICH E6(R3) guidance calls for oversight proportionate to risk and for qualified people to perform trial activities. FDA’s risk-based monitoring guidance recommends timely evaluation of significant findings and follow-up on potential systemic issues. Those principles inform this interview exercise. [1, 2]
Give every candidate the same case
A participant in a fictional oncology trial has received a scheduled dose. The protocol requires the investigator to review a specific safety lab result before dosing. The site coordinator tells the CRA the result was still pending when the dose was given. The CRA has the coordinator’s account and has yet to review the source records.
Ask the candidate what they would do first, which records they would check, and how they would brief the investigator and sponsor contacts named in the study’s escalation plan. Then ask what evidence they would look for at the next comparable dosing visit.
Listen for three decisions
Verify. Confirm the protocol requirement. Reconstruct when the sample was collected, when the result became available to the site, when investigator review was documented, and when the dose was administered. A late entry in the study system can look similar to a result that truly arrived after dosing.
Escalate. A strong candidate raises the potential safety issue promptly while verifying the timeline. One possible answer is “I’d notify the investigator and the designated sponsor contacts now, distinguish the coordinator’s report from what I’ve verified, and check source timestamps in parallel.” The investigator handles participant assessment and clinical care. The sponsor and site follow the applicable study processes for documenting and reporting the event. [1, 2]
Follow through. Confirm that the study team documented its assessment and assigned any corrective action. If the team identifies a weak handoff between the lab and treatment staff, check whether the required review is documented before dosing at subsequent visits. Share the findings with the study team so it can decide whether to examine other sites using the same process.
Score the answer consistently
Score verification, escalation, and follow-through from zero to two each. Give zero if the step is missing, one if the candidate names it in general terms, and two if they specify the evidence, escalation contact and timing, or follow-up check relevant to that step.
Record a separate concern if the candidate would delay a potential safety escalation until the routine monitoring report or take responsibility for a clinical decision. Use the exercise alongside verification of role-relevant experience and study-specific training needs.
What this means for trial teams
A consistent interview makes it easier for sponsors and CROs to compare how candidates handle uncertainty, communicate urgent findings, and follow an action through to the next visit. Those are concrete responsibilities to define in the monitoring assignment and reinforce during onboarding.
Lampgen Clinical Research scopes oncology CRA staffing around the protocol, site coverage, and the monitoring work the study requires. The same questions can help a study team decide what support and escalation access an incoming CRA will need.
Sources
- FDA • ICH E6(R3) Good Clinical Practice, sections 2.7, 3.4 and 3.11 (September 2025)
- FDA • A Risk-Based Approach to Monitoring of Clinical Investigations, questions 6–8 (April 2023)
- Related Lampgen insight • How to evaluate an oncology clinical research associate